Convalescent plasma therapy and donor selection for COVID-19 outbreak: A help from survivors to patients

Abstract

The Coronavirus pandemic, which began in Wuhan-China in December 2019, was evaluated with WHO data. The effectiveness of convalescent plasma therapy in the pandemic was discussed in the present review. The importance of donor selection for this treatment method was emphasized. We offer the world that convalescent plasma therapy should be developed to combat the pandemic. But not all cases have closed, and new cases continue to be diagnosed around the world. The pandemic is very aggressive, and the world is under serious threat. No vaccine or antiviral agent effective on Coronavirus has yet been produced. Each country can combine survivor-induced convalescent plasma treatment into existing treatments until the Coronavirus vaccine and antiviral agent are produced. This method can offer a time-saving treatment option for every country with its advantages such as easy applicability, low cost and limited medical equipment requirements, but vaccine-drug researches should be accelerated internationally. We believe that target donor selection will determine success in convalescent plasma treatment. Multicenter international clinical trials are needed to combat the COVID-19 pandemic and to develop convalescent plasma therapy.